The United Kingdom and the United States have signed a major commercial pact that will guarantee no levies on British medicine products being sold in the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to raise funding on pharmaceuticals through the NHS. This commitment guarantees that tariffs on these crucial goods will remain at nothing for a period of three years.
This deal is in response to earlier warnings to significantly raise tariffs on patented drug products, with potential rates mentioned up to 100%.
"This arrangement with the UK reinforces the international landscape for new treatments and brings much-needed fairness to transatlantic medicine commerce," an announcement noted.
Economic Importance
Medicines are one of the Britain's largest export categories to the United States, which is by far the biggest market for major British pharmaceutical firms.
Trade data indicate that in the year leading up to September, the UK sold pharmaceutical products worth £11.1bn to the US. This value represented 17.4% of British export trade in that timeframe.
"This guarantee safeguards employment, boosts capital expenditure and sets the stage for the UK to establish itself as a worldwide center for medical research," a minister remarked.
Detailed NHS Changes
The pact includes several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a target to double total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The amount manufacturers must pay back to the NHS to prevent overspending will be restricted at fifteen percent. In the past, repayments topped twenty percent.
Industry Background
The pact comes amid a protracted tension between the sector and the ministers over spending levels and NHS adoption.
The disagreement were heightened by claims that American patients were paying significantly more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been halted or cancelled, while substantial funding commitments have been announced toward projects in the United States.
A senior figure stated that the NHS must spend more on treatments, noting that its spending on drugs had declined as a share of its total funding over the last ten years.
